Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for XXXX Arising from Urachus.

@entity1 @entity6628 @entity5 @entity2225 @entity5091 @entity189 @entity4056 @entity1725 @entity5089 @entity5822 @entity420
BACKGROUND: @entity1725 ( @entity1725 ) is a rare locoregional disease characterized by disseminated @entity5 . However, little is known about @entity1725 from urachal @entity5 as a result of its rarity. METHODS: A total of 9 @entity1 with @entity1725 of urachal origin were treated by cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) in our institution. All specimens of surgeries were submitted for pathologic examination. Representative slides of @entity5 and normal urachus were submitted for immunohistochemical staining. RESULTS: Four @entity1 were @entity1 ; the median age was 48  years (range 27-65  years). Initial radiologic examination of all @entity1 showed a @entity5 located between posterior aspect of umbilicus and the dome of urinary bladder, with or without leaking mucin. Complete CRS and HIPEC were performed in all @entity1 . Until the latest follow-up, local recurrence occurred in 1 @entity1 . Other 8 @entity1 had a median disease-free survival of 27.5  months. Primary @entity5 of 9 cases were all mucinous @entity420 . Six @entity1 had low-grade mucinous @entity189 peritonei, and 3 @entity1 had high-grade mucinous @entity189 peritonei. Signet ring cells were noted in 4 @entity1 . All @entity5 specimens of 9 @entity1 were diffusive positive for @entity2225 , @entity6628 , @entity5091 , and @entity5089 , and were variant positive for @entity5822 . CONCLUSIONS: @entity1725 arising from urachus comes from neoplastic cells with development of @entity4056 . It shares a similar pathophysiology as @entity1725 from appendix. CRS including total urethrectomy, partial cystectomy, and peritonectomy plus HIPEC can be considered as a new option of treatment for @entity1725 originating from urachus.
